NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Natco Pharma intends to defend the matter accordingly
The company will respond to the Warning Letter within the stipulated timelines
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
The company is confident of addressing all the observations within the stipulated time
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Subscribe To Our Newsletter & Stay Updated